CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
Pedro RochaRuth SalazarJiexin ZhangDebora LedesmaJose L SolorzanoBarbara MinoPamela VillalobosHitoshi DejimaDzifa Y DouseLixia DiaoKyle Gregory MitchellXiuning LeJianjun ZhangAnnikka WeissferdtEdwin Parra-CuentasTina CasconeDavid C RiceBoris SepesiNeda KalhorCesar MoranAra VaporciyanJohn HeymachDon L GibbonsJ Jack LeeHumam KadaraIgnacio WistubaCarmen BehrensLuisa Maren Solis SotoPublished in: Cancer immunology, immunotherapy : CII (2021)
Our study suggests that higher CD73 expression is associated with an overall augmented host immune response, suggesting potential implications in the immune pathobiology of early stage lung adenocarcinoma. Our findings warrant further studies to explore the role of CD73 in immunotherapeutic response of LUAD.